Literature DB >> 18974549

Duchenne muscular dystrophy.

Eppie M Yiu1, Andrew J Kornberg.   

Abstract

Duchenne muscular dystrophy (DMD), an X-linked disorder, is the most common muscular dystrophy in children, presenting in early childhood and characterized by proximal muscle weakness and calf hypertrophy in affected boys. Patients usually become wheelchair-bound by the age of 12 years, and die of cardiorespiratory complications in their late teens to early twenties. Advances in the management of DMD, including treatment with corticosteroids and the use of intermittent positive pressure ventilation have provided improvements in function, ambulation, quality of life and life expectancy, although novel therapies still aim to provide a cure for this devastating disorder. The clinical features, investigations, and management of DMD are reviewed, as well as the latest in some of the novel therapies.

Entities:  

Mesh:

Year:  2008        PMID: 18974549     DOI: 10.4103/0028-3886.43441

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  15 in total

1.  Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy.

Authors:  Ida Luisa Rotundo; Stefania Faraso; Elvira De Leonibus; Gerardo Nigro; Carmen Vitiello; Alessio Lancioni; Daniele Di Napoli; Sigismondo Castaldo; Vincenzo Russo; Fabio Russo; Giulio Piluso; Alberto Auricchio; Vincenzo Nigro
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

Review 2.  What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?

Authors:  Jennifer Manning; Dervla O'Malley
Journal:  J Muscle Res Cell Motil       Date:  2015-02-11       Impact factor: 2.698

3.  Inspiratory pressure-generating capacity is preserved during ventilatory and non-ventilatory behaviours in young dystrophic mdx mice despite profound diaphragm muscle weakness.

Authors:  David P Burns; Kevin H Murphy; Eric F Lucking; Ken D O'Halloran
Journal:  J Physiol       Date:  2019-01-13       Impact factor: 5.182

Review 4.  Cognitive dysfunction in Duchenne muscular dystrophy: a possible role for neuromodulatory immune molecules.

Authors:  Mark G Rae; Dervla O'Malley
Journal:  J Neurophysiol       Date:  2016-07-06       Impact factor: 2.714

Review 5.  Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy.

Authors:  Jong-Hee Kim; Hyo-Bum Kwak; LaDora V Thompson; John M Lawler
Journal:  J Muscle Res Cell Motil       Date:  2012-10-28       Impact factor: 2.698

Review 6.  Stem cells in clinical practice: applications and warnings.

Authors:  Daniele Lodi; Tommaso Iannitti; Beniamino Palmieri
Journal:  J Exp Clin Cancer Res       Date:  2011-01-17

7.  Post-natal induction of PGC-1α protects against severe muscle dystrophy independently of utrophin.

Authors:  Mun Chun Chan; Glenn C Rowe; Srilatha Raghuram; Ian S Patten; Caitlin Farrell; Zolt Arany
Journal:  Skelet Muscle       Date:  2014-01-22       Impact factor: 4.912

8.  Autologous bone marrow mononuclear cell transplantation in Duchenne muscular dystrophy - a case report.

Authors:  Alok Sharma; Hemangi Sane; Amruta Paranjape; Khushboo Bhagawanani; Nandini Gokulchandran; Prerna Badhe
Journal:  Am J Case Rep       Date:  2014-03-28

9.  Challenges in the management of the child with Duchenne muscular dystrophy in a resource poor setting:a case report.

Authors:  Kelechi Kenneth Odinaka; Emeka Charles Nwolisa
Journal:  Pan Afr Med J       Date:  2014-10-30

10.  Effects of an immunosuppressive treatment in the GRMD dog model of Duchenne muscular dystrophy.

Authors:  Inès Barthélémy; Ane Uriarte; Carole Drougard; Yves Unterfinger; Jean-Laurent Thibaud; Stéphane Blot
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.